Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H19ClFN7 |
Molecular Weight | 387.842 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC(CC1)NC2=NC3=C(NC4=CC=C(F)C(Cl)=C4)N=CN=C3C=N2
InChI
InChIKey=FTFRZXFNZVCRSK-UHFFFAOYSA-N
InChI=1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12008195
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12008195
Falnidamol is an epidermal growth factor receptor inhibitor, developed by Boehringer Ingelheim. Falnidamol demonstrated anticancer activity in vitro. The phase I trial was discontinued due to a dose-limiting increase of liver enzymes, low bioavailability of the drug and the detection of a pharmacologically inactive metabolite.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P00533|||Q9GZX1 Gene ID: 1956.0 Gene Symbol: EGFR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12008195 |
3.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12008195
In a phase I study, patients received falnidamol orally at doses of 25 mg, 50 mg, 100 mg, 200 mg, 150 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11178955
T47D cells were treated with falnidamol at 0.01, 0.03, 0.1, 0.3, 1, 3, 10 uM for 1 h. 3 uM of the drug was sufficient to block signaling by TGF-alpha. 10 uM falnidamol blocked ErbB2 activity efficiently.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2167
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
||
|
NCI_THESAURUS |
C1967
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000127711
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
PRIMARY | |||
|
196612-93-8
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
PRIMARY | |||
|
SUB33798
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
PRIMARY | |||
|
0MU316797D
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
PRIMARY | |||
|
7857
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
PRIMARY | |||
|
DB12966
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
PRIMARY | |||
|
6918508
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
PRIMARY | |||
|
C80868
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
PRIMARY | |||
|
CHEMBL258940
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
PRIMARY | |||
|
DTXSID0048399
Created by
admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY